535
edits
Changes
no edit summary
==State of the Art==
There are various influenza tests available on the market. The most common tests are ‘rapid influenza diagnostic tests’, also called RIDTs. RIDTs provide results in a qualitative way within approximately 10-15 minutes and work by detecting the parts of the virus that stimulate an immune response. <ref name="Arti17">Rapid Influenza Diagnostic Tests, 2016, Centers for Disease Control and Prevention, https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm</ref>
The table contains examples of available Rapid Influenza Diagnostic Tests that provide results in 10-15 minutes.
In the SensUs Competition, a saliva based test will be developed. Moreover, SensUs strives to develop sensors that provide results within 5 minutes and that are as sensitive as possible.The SensUs Competition aims to innovate the field of influenza biosensing by using saliva as a matrix, by the speed of the test, and by targeting a high sensitivity.
{| class="wikitable" style="margin-bottom:0"
!Company
!Product
!Test name
!Sample Volume
!Reportable range
!Dilution ratio*
!Precision
!Incubation time
|-
|Sanquin<ref name=”[27]”>MabTrack level adalimumab (2018). Leaflet ''MabTrack level adalimumab''. Sanquin.</ref>
|M2910
|MabTrack level adalimumab
|5 μL
|1–30 µg/mL
|1:199<br />1:1499<br />1:1999
|Total CV < 15%<br /> Inter-assay: CV < 15.4%
|2 hours 10 min.
|-
|apDia<ref name=”[28]”>apDia Adalimumab ELISA (2016). Leaflet ''apDia Adalimumab ELISA.'' apDia.</ref>
|710201
|apDia Adalimumab ELISA
|10 μL
|0.5-12 µg/mL<br />2.0- 48 µg/mL
|1:99<br />1:399
|Intra-assay: CV < 10.1%<br />Inter-assay: CV< 14.2%
|1 hour 40 min.
|-
|Theradiag<ref name=”[29]”>LTA002 LISA-TRACKER Adalimumab (2017). Leaflet ''LTA002 LISA-TRACKER Adalimumab''. Theradiag.</ref>
|LTA 002
|LISA-TRACKER Adalimumab
|5 μL
|0.3 - 16 µg/mL
|1:200
|Intra-assay: CV < 13.3%<br />Inter-assay: CV< 9.7%
|2 hours
|-
|R-Biopharm AG<ref name=”[30]”>GN3043 RIDA®QUICK ADM Monitoring (2018). Leaflet ''GN3043 RIDA®QUICK ADM Monitoring''. R-Biopharm AG.</ref>
|GN3043
|RIDA®QUICK ADM Monitoring
|20 μL
|0.5 - 25 μg/ml
|1:499
|Intra-assay: CV < 16.8%<br />Inter-assay: CV< 16.6%
|15 min.
|-
|BÜHLMANN<ref name=”[31]”>LF-TLAD25 Quantum Blue® Adalimumab (2018). Leaflet ''LF-TLAD25 Quantum Blue® Adalimumab''. BÜHLMANN.</ref>
|LF-TLAD25
|Quantum Blue® Adalimumab
|10 μL
|1.3 - 35 μg/mL
|1:19
|Intra-assay: CV < 28.6%<br />Inter-assay: CV < 12.6%
|15 min
|}<div style="margin-bottom:1em"><sub>''Table 2: Selection of currently available systems for measuring adalimumab.''<br />*Note: the dilution ratio is defined as 1:x, with x the volume of added reagents relative to the volume of plasma sample</sub></div>